By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Poniard Pharmaceuticals, Inc. 

7000 Shoreline Court
Suite 270
South San Francisco  California  94080  U.S.A.
Phone: 650-583-3774 Fax: 650-583-3789


Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancers. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors.

For additional information, please visit

Key Statistics

Ownership: Public

Web Site: Poniard Pharmaceuticals, Inc.
Symbol: PARD


Company News
Allozyme Cuts Workforce After Scrapping Merger Plan With Poniard Pharmaceuticals, Inc. (PARD); Poniard CEO, 4 Board Members Resign, Company Booted Off Nasdaq 1/4/2012 8:03:52 AM
Poniard Pharmaceuticals, Inc. (PARD) and Allozyme Terminate Planned Merger 12/22/2011 7:00:36 AM
Poniard Pharmaceuticals, Inc. (PARD) Announces Shareholders Approve Merger With Allozyne, Inc. 11/22/2011 7:39:44 AM
Poniard Pharmaceuticals, Inc. (PARD) Announces Licensing Agreement for Focal Adhesion Kinase Technology 11/18/2011 7:35:43 AM
Poniard Pharmaceuticals, Inc. (PARD) Reports Third Quarter 2011 Financial Results 10/31/2011 8:31:12 AM
Poniard Pharmaceuticals, Inc. (PARD) Announces Effectiveness of Form S-4 Registration Statement for the Proposed Merger with Allozyne, Inc. 10/10/2011 9:16:49 AM
Poniard Pharmaceuticals, Inc. (PARD) Receives Favorable NASDAQ Decision for Continued Listing of Company Shares 9/6/2011 9:18:32 AM
Poniard Pharmaceuticals, Inc. (PARD) Reports Second Quarter 2011 Financial Results 8/15/2011 7:59:40 AM
Poniard Pharmaceuticals, Inc. (PARD) Announces Filing of Form S-4 Registration Statement Related to Proposed Merger With Allozyne, Inc. 7/26/2011 9:01:39 AM
Poniard Pharmaceuticals, Inc. (PARD) Adjourns Reconvened Annual Meeting of Shareholders to Solicit Additional Proxies for Important Reverse Stock Split Proposal 7/12/2011 8:31:01 AM